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Abstract Background & Aims: Studies of hepatitis C virus (HCV)
infection, immunopathogenesis, and resulting liver diseases have
been hampered by the lack of a small animal model. We developed
humanized mice with human immune system and liver tissues to
improve the studies of hepatitis C pathogenesis and treatment.
Methods: To promote engraftment of human hepatocytes, we
expressed a fusion protein of the FK506 binding protein (FKBP) and
caspase 8 under the control of the albumin promoter (AFC8), which
induces liver cell death, in Balb/C Rag2/ cC-null mice. Co-transplan-
tation of human CD34+ human hematopoietic stem cells (HSC) and
hepatocyte progenitors into the transgenic mice led to efﬁcient
engraftment of human leucocytes and hepatocytes. We then infected
these humanized mice (AFC8-hu HSC/Hep) with primary HCV isolates
and studied HCV-induced immune responses and liver diseases.
Results: AFC8-hu HSC/Hep mice supported HCV infection in the liver
and generated a human immune T-cell response against HCV. HCV
infection induced liver inﬂammation, hepatitis, and ﬁbrosis, which
correlated with activation of stellate cells and expression of human
ﬁbrogenic genes.
Conclusions: AFC8-hu HSC/Hep mice are a useful model of HCV
infection, the immune response, and liver disease, because they
contain human immune system and liver cells. These mice become
infected with HCV, generate a speciﬁc immune response againstJournal of Hepatology 20
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urokinase-like plasminogen Activator.ﬁbrosis. This model might also be used to develop therapeutics for
HCV infection.
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by Elsevier B.V. Open access under CC BY-NC-ND license.The development of efﬁcient antiviral preventive and therapeutic
strategies and vaccines against hepatitis C virus (HCV) infection
has been hampered by the lack of a convenient small animal
model. Indeed, mouse hepatocytes are naturally resistant to
HCV infection [1]. Although the chimpanzee has markedly con-
tributed to our current understanding of HCV infection [2], this
model is characterized by limited availability, high costs, and
important ethical restrictions. Alternative models based on trans-
plantation of primary human hepatocytes in transgenic immuno-
deﬁcient mice with hepatocyte-lethal phenotype (uPA/SCID [3]
and Fah/Rag2/IL2r/ mice [4]) have laid the foundation for the
establishment of a small animal model for the study of HCV
infection. Due to their immunodeﬁciency, these mice can be
successfully transplanted with primary human hepatocytes and
subsequently infected with human hepatotropic viruses. To date,
these mice are the most advanced small animal model to study
HCV infection. However, these models are limited by high mor-
tality and variable robustness of infection. Furthermore, the
absence of a functional immune system hampers a comprehen-
sive investigation of HCV–host interactions and the evaluation
of immunotherapeutic approaches and vaccines. Two major
strategies are currently pursued to develop immunocompetent
HCV mouse models: (i) development of transgenic animals
expressing human-speciﬁc restriction factors required for the
viral life cycle and (ii) chimeric mice containing a human liver
and immune system.
In a recent study [5] published in Gastroenterology, Washburn
and colleagues from Dr. Su’s lab at the Lineberger Comprehensive
Cancer Center, University of North Carolina, Chapel Hill, USA,
report the development of a chimeric mouse model permissive
for low-level HCV infection and containing a partially reconsti-
tuted human immune system. The authors used human foetal
liver as a dual source of human hepatocyte progenitor cells
(Hep) and CD34+ hematopoietic stem cells (HSCs) and trans-
planted these cells into Rag2/IL2r/ Balb/c immunodeﬁcient
mice (Fig. 1). Induction of a mouse liver environment allowing
engraftment of human Hep cells was obtained by the liver-spe-11 vol. 55 j 718–720
Fig. 1. HCV infection of AFC8 mice humanized with foetal liver hepatocyte progenitor cells (Hep) and CD34+ hematopoietic stem cells (HSCs) as described by
Washburn and colleagues [5]. (A) Induction of a mouse liver environment allowing engraftment of human hepatocytes progenitor cells (Hep). The FK506 binding protein-
Caspase 8 (AFC8) fusion protein, whose transgenic expression under the control of the albumin promoter is restricted to murine hepatocytes, is dimerized in the presence of
the AP20187 prodrug, leading to apoptosis of murine hepatocytes. (B) Human foetal liver is used as a dual source of Hep cells and CD34+ hematopoietic stem cells (HSCs)
injected in the liver of Rag2/IL2r/ Balb/c immunodeﬁcient mice transgenic for the AFC8 suicide gene. The AP20187 prodrug is then injected to induce death of AFC8-
expressing murine hepatocytes allowing repopulation of human Hep cells that can be infected by HCV. In parallel, HSC reconstitute a human immune system that
comprises antiviral cellular immune responses. Limitations include the low level of HCV infection with the absence of HCV in the serum of infected mice and the lack of a
fully functional B-cell response with the absence of neutralizing antibodies. A functional cellular immune system may allow the study of HCV/HIV co-infections in the
future.
JOURNAL OF HEPATOLOGYciﬁc expression of a FK506 binding protein-caspase 8 (AFC8)
fusion suicide gene under the control of the albumin promoter
(Fig. 1). The co-injection of foetal liver Hep cells and HSCs into
the liver of newborns led to a signiﬁcant repopulation of human
hepatocytes as shown by immunohistochemistry and human
albumin production. Low-level viral RNA was detected in the
liver of a fraction of the reconstituted mice, but not in the control
mice. Furthermore, human CD4+ and CD8+ T, NK, plasmacytoïd,
and myeloid dendritic cells were detected in the humanized liver.
Evidence for HCV-speciﬁc T-cell responses was demonstrated by
speciﬁc expansion of human T cells from HCV-infected mice
stimulated with HCV peptides, and by intracellular cytokine
staining of CD4+ and CD8+ T cells. Finally, a signiﬁcant leucocyte
liver inﬁltrate was observed in the liver of infected AFC8-hu HSC/
Hep mice. Since HCV-infected mice appeared to develop liverJournal of Hepatology 201ﬁbrosis, the authors concluded that the model may also allow
to study the HCV-induced liver disease.
These results are clearly an important step towards the
development of a mouse model permissive for HCV infection
and containing a human immune system. However, despite
these very promising results, several drawbacks still limit the
use of this model. First, HCV was detectable at low levels only
in the liver of part of the animals and could not be detected in
the serum of the infected mice. The limited robustness is a
challenge for the study of HCV–host interactions. This may be
due to insufﬁcient repopulation level, since immunohistological
analysis reported 10–30% liver repopulation by Hep cells.
Although such repopulation levels have been reported to be
sufﬁcient to obtain sustained HBV infection, more than 50%
repopulation are usually considered to be required for robust1 vol. 55 j 718–720 719
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persistent HCV infection [3,4]. One possible explanation for this
insufﬁcient repopulation level may be the source of hepatocytes.
Indeed, adult primary human hepatocytes remain to date the
most efﬁcient source for liver repopulation and the only one
allowing to reach high levels of HCV infection, as compared with
other sources of progenitor cells, such as induced pluripotent
stem cells, embryonic stem cells [6] or hSCs [7]. Another possi-
bility is the use of a suicide gene as a means to induce the mouse
liver deﬁciency. Indeed, the transient increase of ALT serum
levels after induction of hepatocyte death by injection of the
prodrug AP20187 suggests that it induces an acute liver injury,
which may be suboptimal for liver repopulation, as compared
with chronic liver injury within the uPA-SCID and Fah back-
ground [8]. Optimizing the conditions for induction of murine
hepatocyte death may help to improve liver repopulation.
Assessing the foetal liver as a dual source of Hep cells and HSCs
in other mouse strains, such as uPA/SCID, Fah/Rag2/IL2r/, or
uPA/Rag2/IL2r/ [6] mice could help to address this issue.
Finally, another interesting hypothesis is that the low level of
HCV infection could result from the induction of HCV-speciﬁc
T-cell responses: depletion of human CD4 and/or CD8 T cells
in AFC8-hu HSC/Hep mice or comparing the levels of HCV infec-
tion in AFC8-hu Hep versus AFC8-hu Hep/HSC mice will help
answer this question.
A second important drawback is the absence of antibody
responses due to the lack of reconstitution of fully functional
B cells. Antibodies have been shown to play an important role
in the pathogenesis of HCV infection and viral persistence
[9,10]. Furthermore, induction of B cell responses most likely will
be required for the development of effective preventive vaccines.
Thus, the lack of antibody response in this model hampers the
study of mechanisms of immune escape from neutralizing
antibodies or the evaluation of B-cell vaccines.
In conclusion, this study provides a ﬁrst and important step
for the development of immune-competent mouse models of
HCV infection. However, more work needs to be done to
develop a mouse model with robust HCV infection and a more
complete immune system including B-cell reconstitution and
neutralizing antibody responses. The results obtained by
Washburn and colleagues [5] and the rapid advancement in
the production of differentiated tissues from progenitor [6] or
stem cells [7] raise hope that the development of a robust and
fully immune-competent HCV mouse model is a realistic goal
for the near future.720 Journal of Hepatology 201Acknowledgements
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